KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
Medical - Instruments & Supplies
Market Cap$1.26B
5Y Perf.-13.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KMTS vs AMAT
Revenue, margins, valuation, and 5-year total return — side by side.
AMAT
Applied Materials, Inc.
Semiconductors
Market Cap$325.54B
5Y Perf.+182.9%
KMTS vs AMAT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KMTS | AMAT |
|---|---|---|
| Industry | Medical - Instruments & Supplies | Semiconductors |
| Market Cap | $1.26B | $325.54B |
| Revenue (TTM) | $84M | $28.37B |
| Net Income (TTM) | $-145M | $7.00B |
| Gross Margin | 48.8% | 48.7% |
| Operating Margin | -171.5% | 29.2% |
| Forward P/E | — | 37.1x |
| Total Debt | $44M | $6.55B |
| Cash & Equiv. | $238M | $7.24B |
KMTS vs AMAT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KMTS
AMAT
| Stock | Mar 25 | May 26 | Return |
|---|---|---|---|
| KESTRA MEDICAL TECH… (KMTS) | 100 | 86.4 | -13.6% |
| Applied Materials, … (AMAT) | 100 | 282.9 | +182.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KMTS vs AMAT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: AMAT leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and dividend income and shareholder returns. KESTRA MEDICAL TECHNOLOGIES, LTD. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
KMTS
KESTRA MEDICAL TECHNOLOGIES, LTD.
The Growth Play
KMTS is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 115.1%, EPS growth -151.5%
- Lower volatility, beta 1.87, Low D/E 21.6%, current ratio 6.72x
- Beta 1.87, yield 0.2%, current ratio 6.72x
Best for: growth exposure and sleep-well-at-night
AMAT
Applied Materials, Inc.
The Income Pick
AMAT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 8 yrs, beta 2.14, yield 0.4%
- 20.1% 10Y total return vs KMTS's -1.5%
- 24.7% margin vs KMTS's -173.0%
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KMTS | 115.1% revenue growth vs AMAT's 4.4% |
| Quality / Margins | AMAT | 24.7% margin vs KMTS's -173.0% |
| Stability / Safety | KMTS | Beta 1.87 vs AMAT's 2.14, lower leverage |
| Dividends | AMAT | 0.4% yield, 8-year raise streak, vs KMTS's 0.2% |
| Momentum (1Y) | AMAT | +164.7% vs KMTS's -1.5% |
| Efficiency (ROA) | AMAT | 19.3% ROA vs KMTS's -48.8%, ROIC 33.3% vs -6.6% |
KMTS vs AMAT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2024
KMTS vs AMAT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAMATLAGGINGKMTS
KMTSKESTRA MEDICAL TECHNO…
1leads
AMATApplied Materials, In…
4leads
6 Total Categories
CATEGORYLEADERvs KMTSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
AMAT4/6
Valuation MetricsMultiples, price ratios, and targets
KMTS2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
AMAT7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
AMAT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
AMAT2/2
Income & Cash Flow (Last 12 Months)
AMAT leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMAT is the larger business by revenue, generating $28.4B annually — 338.8x KMTS's $84M. AMAT is the more profitable business, keeping 24.7% of every revenue dollar as net income compared to KMTS's -173.0%. On growth, KMTS holds the edge at +62.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KMTSKESTRA MEDICAL TE… | AMATApplied Materials… |
|---|---|---|
| RevenueTrailing 12 months | $84M | $28.4B |
| EBITDAEarnings before interest/tax | -$142M | $8.4B |
| Net IncomeAfter-tax profit | -$145M | $7.0B |
| Free Cash FlowCash after capex | -$120M | $5.7B |
| Gross MarginGross profit ÷ Revenue | +48.8% | +48.7% |
| Operating MarginEBIT ÷ Revenue | -171.5% | +29.2% |
| Net MarginNet income ÷ Revenue | -173.0% | +24.7% |
| FCF MarginFCF ÷ Revenue | -143.3% | +20.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +62.7% | -3.5% |
| EPS Growth (YoY)Latest quarter vs prior year | -22.0% | +13.9% |
AMAT leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
KMTS leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | KMTSKESTRA MEDICAL TE… | AMATApplied Materials… |
|---|---|---|
| Market CapShares × price | $1.3B | $325.5B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $324.9B |
| Trailing P/EPrice ÷ TTM EPS | -4.19x | 47.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 37.07x |
| PEG RatioP/E ÷ EPS growth rate | — | 2.76x |
| EV / EBITDAEnterprise value multiple | — | 38.68x |
| Price / SalesMarket cap ÷ Revenue | 20.99x | 11.48x |
| Price / BookPrice ÷ Book value/share | 5.19x | 16.25x |
| Price / FCFMarket cap ÷ FCF | — | 57.13x |
KMTS leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
AMAT leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
AMAT delivers a 34.3% return on equity — every $100 of shareholder capital generates $34 in annual profit, vs $-69 for KMTS. KMTS carries lower financial leverage with a 0.22x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMAT's 0.32x. On the Piotroski fundamental quality scale (0–9), AMAT scores 7/9 vs KMTS's 6/9, reflecting strong financial health.
| Metric | KMTSKESTRA MEDICAL TE… | AMATApplied Materials… |
|---|---|---|
| ROE (TTM)Return on equity | -68.8% | +34.3% |
| ROA (TTM)Return on assets | -48.8% | +19.3% |
| ROICReturn on invested capital | -6.6% | +33.3% |
| ROCEReturn on capital employed | -78.6% | +30.6% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.22x | 0.32x |
| Net DebtTotal debt minus cash | -$193M | -$686M |
| Cash & Equiv.Liquid assets | $238M | $7.2B |
| Total DebtShort + long-term debt | $44M | $6.6B |
| Interest CoverageEBIT ÷ Interest expense | -13.93x | 35.46x |
AMAT leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
AMAT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in AMAT five years ago would be worth $31,383 today (with dividends reinvested), compared to $9,853 for KMTS. Over the past 12 months, AMAT leads with a +164.7% total return vs KMTS's -1.5%. The 3-year compound annual growth rate (CAGR) favors AMAT at 53.1% vs KMTS's -0.5% — a key indicator of consistent wealth creation.
| Metric | KMTSKESTRA MEDICAL TE… | AMATApplied Materials… |
|---|---|---|
| YTD ReturnYear-to-date | -11.8% | +52.9% |
| 1-Year ReturnPast 12 months | -1.5% | +164.7% |
| 3-Year ReturnCumulative with dividends | -1.5% | +258.7% |
| 5-Year ReturnCumulative with dividends | -1.5% | +213.8% |
| 10-Year ReturnCumulative with dividends | -1.5% | +2014.4% |
| CAGR (3Y)Annualised 3-year return | -0.5% | +53.1% |
AMAT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KMTS and AMAT each lead in 1 of 2 comparable metrics.
Risk & Volatility
KMTS is the less volatile stock with a 1.87 beta — it tends to amplify market swings less than AMAT's 2.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. AMAT currently trades 94.8% from its 52-week high vs KMTS's 71.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KMTSKESTRA MEDICAL TE… | AMATApplied Materials… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 2.14x |
| 52-Week HighHighest price in past year | $30.00 | $432.81 |
| 52-Week LowLowest price in past year | $13.25 | $151.51 |
| % of 52W HighCurrent price vs 52-week peak | +71.7% | +94.8% |
| RSI (14)Momentum oscillator 0–100 | 48.1 | 66.3 |
| Avg Volume (50D)Average daily shares traded | 357K | 6.0M |
Evenly matched — KMTS and AMAT each lead in 1 of 2 comparable metrics.
Analyst Outlook
AMAT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates KMTS as "Buy" and AMAT as "Buy". Consensus price targets imply 30.1% upside for KMTS (target: $28) vs 3.9% for AMAT (target: $426). For income investors, AMAT offers the higher dividend yield at 0.42% vs KMTS's 0.16%.
| Metric | KMTSKESTRA MEDICAL TE… | AMATApplied Materials… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $28.00 | $426.39 |
| # AnalystsCovering analysts | 4 | 53 |
| Dividend YieldAnnual dividend ÷ price | +0.2% | +0.4% |
| Dividend StreakConsecutive years of raises | 5 | 8 |
| Dividend / ShareAnnual DPS | $0.03 | $1.71 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.5% |
AMAT leads this category, winning 2 of 2 comparable metrics.
Key Takeaway
AMAT leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KMTS leads in 1 (Valuation Metrics). 1 tied.
Best OverallApplied Materials, Inc. (AMAT)Leads 4 of 6 categories
Loading custom metrics...
KMTS vs AMAT: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is KMTS or AMAT a better buy right now?
For growth investors, KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) is the stronger pick with 115. 1% revenue growth year-over-year, versus 4. 4% for Applied Materials, Inc. (AMAT). Applied Materials, Inc. (AMAT) offers the better valuation at 47. 4x trailing P/E (37. 1x forward), making it the more compelling value choice. Analysts rate KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KMTS or AMAT?
Over the past 5 years, Applied Materials, Inc.
(AMAT) delivered a total return of +213. 8%, compared to -1. 5% for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS). Over 10 years, the gap is even starker: AMAT returned +20. 1% versus KMTS's -1. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KMTS or AMAT?
By beta (market sensitivity over 5 years), KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) is the lower-risk stock at 1. 87β versus Applied Materials, Inc. 's 2. 14β — meaning AMAT is approximately 14% more volatile than KMTS relative to the S&P 500. On balance sheet safety, KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) carries a lower debt/equity ratio of 22% versus 32% for Applied Materials, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — KMTS or AMAT?
By revenue growth (latest reported year), KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) is pulling ahead at 115. 1% versus 4. 4% for Applied Materials, Inc. (AMAT). On earnings-per-share growth, the picture is similar: Applied Materials, Inc. grew EPS 0. 6% year-over-year, compared to -151. 5% for KESTRA MEDICAL TECHNOLOGIES, LTD.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KMTS or AMAT?
Applied Materials, Inc.
(AMAT) is the more profitable company, earning 24. 7% net margin versus -190. 3% for KESTRA MEDICAL TECHNOLOGIES, LTD. — meaning it keeps 24. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMAT leads at 29. 2% versus -177. 8% for KMTS. At the gross margin level — before operating expenses — AMAT leads at 48. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is KMTS or AMAT more undervalued right now?
Analyst consensus price targets imply the most upside for KMTS: 30.
1% to $28. 00.
07Which pays a better dividend — KMTS or AMAT?
All stocks in this comparison pay dividends.
Applied Materials, Inc. (AMAT) offers the highest yield at 0. 4%, versus 0. 2% for KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS).
08Is KMTS or AMAT better for a retirement portfolio?
For long-horizon retirement investors, KESTRA MEDICAL TECHNOLOGIES, LTD.
(KMTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Applied Materials, Inc. (AMAT) carries a higher beta of 2. 14 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KMTS: -1. 5%, AMAT: +20. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between KMTS and AMAT?
These companies operate in different sectors (KMTS (Healthcare) and AMAT (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: KMTS is a small-cap high-growth stock; AMAT is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(KMTS: 62.7% · AMAT: -3.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.